Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717595 | 0.71 | KIF11 (0.44) | KIF11MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL16571050 | 0.71 | MAP2 (0.46) | KIF11MEN1KMT2AMAP2K4 | |
| SCHEMBL31025910 | 0.71 | MAPT (0.55) | KIF11MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL4616764 | 0.71 | KMT2A (0.64) | KIF11MEN1KMT2AMAPTALDH1A1 | |
| Guanidine SCHEMBL8688379 | 0.70 | KMT2A (0.56) | KIF11MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL8689814 | 0.70 | MEN1 (0.62) | KIF11MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL28780 | 0.69 | MAPT (0.54) | KIF11MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL16571711 | 0.69 | KIF11 (0.39) | KIF11MAP2K4 | |
| SCHEMBL30039894 | 0.68 | PARP1 (0.50) | KIF11MAPTCA12CA9 | |
| SCHEMBL28961839 | 0.68 | PARP1 (0.50) | KIF11MAPTCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618129-B2 | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| US-20120053203-A1 | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053203-A1 | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | KIF11 3846/4885MEN1 2626/4885KMT2A 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.